The prospects and challenges of the use of cell-free DNA as a diagnostic and prognostic biomarker for oral cancer in Sub-Saharan Africa
Blood-based cancer tests adapted for African settings could help detect oral cancer earlier where delayed diagnosis drives high mortality.
Oral cancer morbidity and mortality are rising in Sub-Saharan Africa due to delayed diagnosis, poor infrastructure, and socioeconomic barriers; this review evaluates cfDNA liquid biopsy as a minimally invasive diagnostic tool applicable to SSA's oral cancer burden. The review identifies the need for population-specific validation, multicentre SSA data panels, and adaptation of existing cfDNA protocols to resource-limited settings.
What the study was
- Study design
- Narrative review
- Category
- T3: Early cancer detection
- Maturity
- Exploratory
- Journal
- The Journal of Liquid Biopsy
Why it surfaced
Addresses significant unmet need in an underserved population where oral cancer is a growing public health problem; cfDNA liquid biopsy aligns directly with early cancer detection watchlist goals and highlights global equity dimensions of diagnostic innovation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.